ENZO BIOCHEM INC
ENZBHealthcare · Biological Products, (No Diagnostic Substances) · NY · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $31.9M | $31.1M | $32.6M | $117.7M | $76.0M | $81.2M |
| Operating income | −$12.4M | −$24.7M | −$17.0M | $692,000 | −$30.4M | $1.7M |
| Net income | −$26.1M | $20.3M | −$18.3M | $7.9M | −$28.5M | $2.5M |
| Total assets | $85.8M | $121.9M | $75.6M | $113.7M | $112.5M | $106.6M |
| Total liabilities | $29.7M | $43.4M | $21.1M | $45.1M | $54.2M | $20.6M |
| Equity | $56.1M | $78.5M | $54.5M | $68.6M | $58.4M | $86.0M |
| EPS (diluted) | $-0.51 | $0.41 | $-0.38 | $0.16 | $-0.60 | $0.05 |
| Shares out. | 52.2M | 50.5M | 48.7M | 48.5M | 47.9M | 47.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −38.8%
- Net margin
- −81.7%
- Return on equity
- −46.5%
- Return on assets
- −30.4%
- Return on capital (ROCE)
- −20.3%
- Liabilities / assets
- 34.6%
- Debt / equity
- 0.53×
- Book value / share
- $1.07
- Revenue growth (YoY)
- 2.7%
- Net income growth (YoY)
- −228.5%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -6.71distress
- Accruals / assets
- 0.2%clean
- Beneish M-Score
- -2.74normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Oct 31, 2023
- NT 10-Qmissed a reporting deadline ↗Jun 9, 2023
- NT 10-Qmissed a reporting deadline ↗Mar 14, 2023
- NT 11-Kmissed a reporting deadline ↗Jun 28, 2013
- NT 11-Kmissed a reporting deadline ↗Jun 30, 2009
- NT 10-Qmissed a reporting deadline ↗Jun 10, 2009
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Beryl Capital Management LlcPassive (13G)Nov 14, 2025
- Radoff Bradley LouisActivist (13D)Aug 22, 2025
- Battery Ventures Xiv, L.P.Activist (13D)Jun 30, 2025
- Harbert Discovery Fund, LpActivist (13D)Jun 25, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Aug 15, 2025 | 271,993 | 3.8 | -2.5% |
| Jul 31, 2025 | 278,912 | 2.2 | +1.4% |
| Jul 15, 2025 | 275,008 | 1.0 | -2.2% |
| Jun 30, 2025 | 281,268 | 1.0 | +1.7% |
| Jun 13, 2025 | 276,455 | 4.3 | +0.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsAug 20, 2025
- Shareholder voteAug 19, 2025
- Entered a material agreement · Regulation FD disclosureJun 24, 2025
- Other material eventApr 22, 2025
- Delisting / listing-standard noticeApr 21, 2025
- Delisting / listing-standard notice · Regulation FD disclosureMar 31, 2025
- Results of operationsMar 18, 2025
- Shareholder voteJan 16, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/ANov 14, 2025
- EFFECTAug 29, 2025
- EFFECTAug 29, 2025
- SCHEDULE 13D/AAug 22, 2025
- 15-12GFORM 15-12GAug 20, 2025
- S-8 POSPOST-EFFECTIVE AMENDMENT NO TO FORM S-8Aug 20, 2025
- S-8 POSPOST-EFFECTIVE AMENDMENT NO TO FORM S-8Aug 20, 2025
- S-8 POSPOST-EFFECTIVE AMENDMENT NO TO FORM S-8Aug 20, 2025
- S-8 POSPOST-EFFECTIVE AMENDMENT NO TO FORM S-8Aug 20, 2025
- S-8 POSPOST-EFFECTIVE AMENDMENT NO TO FORM S-8Aug 20, 2025
- S-8 POSPOST-EFFECTIVE AMENDMENT NO TO FORM S-8Aug 20, 2025
- S-8 POSPOST-EFFECTIVE AMENDMENT NO TO FORM S-8Aug 20, 2025
- S-8 POSPOST-EFFECTIVE AMENDMENT NO TO FORM S-8Aug 20, 2025
- S-8 POSPOST-EFFECTIVE AMENDMENT NO TO FORM S-8Aug 20, 2025
- S-8 POSPOST-EFFECTIVE AMENDMENT NO TO FORM S-8Aug 20, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.